Direct-acting antivirals (DAAs) are effective for chronic hepatitis C even in elderly adults, resulting in respectable rates sustained virological response (SVR) independently of age, a recent study has shown.
The chlamydia vaccine candidate CTH522 shows therapeutic potential in a phase I trial, being safe and well tolerated when adjuvanted with either CAF01 liposomes or aluminium hydroxide. Both vaccine formulations induce anti-CTH522 IgG seroconversion, although CTH522:CAF01 has a better immunogenicity profile.
Maternal bacterial infections during pregnancy appears to increase the risk for psychotic disorders in offspring, a recent study has shown. This association varies by infection severity and offspring sex.
Use of direct-acting antivirals to treat hepatitis C virus (HCV) in hepatocellular carcinoma (HCC) patients with documented response to therapy appears to yield a significant reduction in mortality, as shown in a recent study.
Use of direct acting antivirals (DAAs) to treat hepatitis C virus (HCV) infection is feasible during pregnancy, as these drugs are highly effective and treatment duration is relatively short, according to a study. In addition, DAA treatment helps improve maternal health and prevent vertical transmission.
The combination of sofosbuvir and velpatasvir is safe and effective for the treatment of hepatitis C virus (HCV) in patients with end-stage renal disease (ESRD) undergoing haemodialysis, a study has shown.
The combination of sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is safe and effective as rescue therapy for hepatitis C patients in whom prior direct-acting antivirals (DAAs) had failed, a new study has found.
In children admitted for orbital complications of acute rhinosinusitis (ARS), the most important causes of medical treatment failure are older age and stage II/III orbital complications at presentation, a recent study has shown.